# Medicare and Medicaid Programs; Regulation To Require Drug Pricing Transparency
> **Centers for Medicare and Medicaid Services** · Final rule. · Published 2019-05-10 · Effective 2019-07-09 · 84 FR 20732
## Document
- **Document number:** 2019-09655
- **Category:** medicare
- **Sub-agency:** Centers for Medicare and Medicaid Services
- **Federal Register citation:** 84 FR 20732
- **CFR reference:** 42 CFR 403
- **Publication date:** 2019-05-10
- **Effective date:** 2019-07-09
- **HHS docket:** CMS-4187-F
## Abstract

This final rule revises the Federal Health Insurance Programs for the Aged and Disabled by amending regulations for the Medicare Parts A, B, C and D programs, as well as the Medicaid program, to require direct-to-consumer (DTC) television advertisements of prescription drugs and biological products for which payment is available through or under Medicare or Medicaid to include the Wholesale Acquisition Cost (WAC or list price) of that drug or biological product. This rule is intended to improve the efficient administration of the Medicare and Medicaid programs by ensuring that beneficiaries are provided with relevant information about the costs of prescription drugs and biological products so they can make informed decisions that minimize their out-of-pocket (OOP) costs and expenditures borne by Medicare and Medicaid, both of which are significant problems.

## Source
- [Federal Register document](https://www.federalregister.gov/documents/2019/05/10/2019-09655/medicare-and-medicaid-programs-regulation-to-require-drug-pricing-transparency)
---
*AI Analytics · CC0 1.0*